BeOne Medicines (ONC) EBITDA (2015 - 2026)
BeOne Medicines (ONC) reported EBITDA of $249.9 million for Q1 2026, up 2150.96% year-over-year from $11.1 million in Q1 2025, and up 35.06% on a QoQ basis from $185.0 million in Q4 2025.
BeOne Medicines (ONC) has 12 years of EBITDA data on file, last reported at $249.9 million in Q1 2026.
- Quarterly EBITDA rose 2150.96% year-over-year to $249.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $685.9 million (up 331.93% YoY) and the FY2025 annual result came in at $447.1 million, up 178.69% from the prior year.
- EBITDA grew to $249.9 million in Q1 2026 per ONC's latest filing, from $185.0 million in the prior quarter.
- Across five years, EBITDA topped out at $249.9 million in Q1 2026 and bottomed at -$468.6 million in Q4 2022.
- The 5-year median for EBITDA is -$134.0 million (2023), against an average of -$168.7 million.
- The widest annual swing landed in 2022, when EBITDA sank 731.76%; it then jumped 2150.96% in 2026.
- Tracing ONC's EBITDA over 5 years: stood at -$468.6 million in 2022, then increased by 18.1% to -$383.8 million in 2023, then jumped by 79.31% to -$79.4 million in 2024, then jumped by 332.97% to $185.0 million in 2025, then soared by 35.06% to $249.9 million in 2026.
- Per Business Quant, the three latest ONC EBITDA figures stand at $249.9 million (Q1 2026), $185.0 million (Q4 2025), and $163.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 661.60 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | -3.82 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 201.19 Mn |
| 10 | BeOne Medicines | - | - | 1.35 Bn | 249.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 249.90 Mn |
| Dec 31, 2025 | 185.04 Mn |
| Sep 30, 2025 | 163.11 Mn |
| Jun 30, 2025 | 87.89 Mn |
| Mar 31, 2025 | 11.10 Mn |
| Dec 31, 2024 | -79.43 Mn |
| Sep 30, 2024 | -120.27 Mn |
| Jun 30, 2024 | -107.16 Mn |
| Mar 31, 2024 | -261.35 Mn |
| Dec 31, 2023 | -383.80 Mn |
| Sep 30, 2023 | -133.97 Mn |
| Jun 30, 2023 | -318.72 Mn |
| Mar 31, 2023 | -371.26 Mn |
| Dec 31, 2022 | -468.62 Mn |
| Sep 30, 2022 | -438.36 Mn |
| Jun 30, 2022 | -439.40 Mn |
| Mar 31, 2022 | -443.29 Mn |
| Dec 31, 2021 | 190.56 Mn |
| Sep 30, 2021 | -462.33 Mn |
| Jun 30, 2021 | -474.84 Mn |
| Mar 31, 2021 | 70.17 Mn |
| Dec 31, 2020 | -484.91 Mn |
| Sep 30, 2020 | -440.14 Mn |
| Jun 30, 2020 | -358.88 Mn |
| Mar 31, 2020 | -373.76 Mn |
| Dec 31, 2019 | -388.04 Mn |
| Sep 30, 2019 | -312.27 Mn |
| Jun 30, 2019 | -85.83 Mn |
| Mar 31, 2019 | -173.76 Mn |
| Dec 31, 2018 | -280.81 Mn |
| Sep 30, 2018 | -151.10 Mn |
| Jun 30, 2018 | -163.05 Mn |
| Mar 31, 2018 | -110.81 Mn |
| Dec 31, 2017 | -103.80 Mn |
| Sep 30, 2017 | 114.91 Mn |
| Jun 30, 2017 | -58.02 Mn |
| Mar 31, 2017 | -51.54 Mn |
| Dec 31, 2016 | -37.27 Mn |
| Sep 30, 2016 | -34.83 Mn |
| Jun 30, 2016 | -24.63 Mn |
| Mar 31, 2016 | -20.33 Mn |
| Dec 31, 2015 | -26.38 Mn |
| Sep 30, 2015 | -13.99 Mn |
| Jun 30, 2015 | -6.57 Mn |
| Mar 31, 2015 | -9.81 Mn |